Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2044

A U.S. company’s 14-foot-tall spacecraft began speeding to the moon, where the vehicle is expected to try to make history by pulling off the first-ever commercial lunar landing.

The lander, called Odysseus and developed by Houston-based Intuitive Machines, isn’t carrying crew, but rather is ferrying scientific and commercial payloads. It was launched at 1:05 a.m. ET Thursday from NASA’s Kennedy Space Center in Florida on a SpaceX rocket and later separated from the upper part of that vehicle to start a roughly 239,000-mile journey, according to a livestream.

The spacecraft had a successful launch and connected to radio communications with the company’s mission operations center in Houston, Intuitive Machines said.

Read more | >

No American spacecraft has made a soft landing on the Moon since NASA’s Apollo 17 in 1972, but that could change soon as the Intuitive Machines’ Nova-C lander launched from the historic Launch Complex 39A at NASA’s Kennedy Space Center at 1:05 am EST (10:05 pm PST) last night. With a currently scheduled landing date of February 22, Nova-C (also called IM-1 Odysseus) is slated to land in Malapert-A crater, which is approximately 190 miles (300 kilometers) from the Moon’s south pole. This landing will also mark the first time a private company will perform a soft landing on the Moon and holds the potential to test technologies that could be used on future human missions with NASA’s Artemis program.

“NASA scientific instruments are on their way to the Moon – a giant leap for humanity as we prepare to return to the lunar surface for the first time in more than half a century,” NASA Administrator Bill Nelson said in a statement. “These daring Moon deliveries will not only conduct new science at the Moon, but they are supporting a growing commercial space economy while showing the strength of American technology and innovation. We have so much to learn through CLPS flights that will help us shape the future of human exploration for the Artemis Generation.”

The science instruments that will be traveling with Nova-C include the Lunar Node 1 Navigation Demonstrator, Laser Retroreflector Array, Navigation Doppler Lidar for Precise Velocity and Range Sensing, Radio Frequency Mass Gauge, Radio-wave Observations at the Lunar Surface of the Photoelectron Sheath, and Stereo Cameras for Lunar Plume-Surface Studies. All these instruments are designed to investigate how spacecraft can both land and operate on the lunar surface, specifically near the south pole of the Moon.

Read more | >

Previous research has suggested that false-positive mammogram results are associated with higher risk for subsequently developing breast cancer. To further examine this issue, researchers in Sweden used national mammography data to follow 500,000 women (median age, 52) during 30 years (1991–2020). About 45,000 women had false-positive results (i.e., they were recalled for further evaluation but didn’t receive diagnoses of breast cancer at that time). Women with false-positive results were matched with controls to compare rates of subsequent breast cancer diagnosis.

The results include:

Read more | >

Our understanding of how galaxies form and the nature of dark matter could be completely upended after new observations of a stellar population bigger than the Milky Way from more than 11 billion years ago that should not exist.

A paper published today in Nature details findings using new data from the James Webb Space Telescope (JWST). The results find that a in the —observed 11.5 billion years ago (a cosmic redshift of 3.2)—has an extremely old population of stars formed much earlier—1.5 billion years earlier in time (a redshift of around 11). The observation upends current modeling, as not enough dark matter has built up in sufficient concentrations to seed their formation.

Swinburne University of Technology’s Distinguished Professor Karl Glazebrook led the study and the international team, who used the JWST for spectroscopic observations of this massive quiescent galaxy.

Read more | >

OpenAI is looking to hire an “insider risk investigator” to “fortify our organization against internal security threats.”

According to the company’s job listing, first spotted by MSPowerUser, the gumshoe is supposed to help the company safeguard its assets by “analyzing anomalous activities, promoting a secure culture, and interacting with various departments to mitigate risks.” Per the Wayback Machine, the job listing has been up since mid-January.

“You’ll play a crucial role in safeguarding OpenAI’s assets by analyzing anomalous activities, promoting a secure culture, and interacting with various departments to mitigate risks,” the listing reads. “Your expertise will be instrumental in protecting OpenAI against internal risks, thereby contributing to the broader societal benefits of artificial intelligence.”

Read more | >

Editor’s note: This story is part of Meet a UChicagoan, a regular series focusing on the people who make UChicago a distinct intellectual community. Read about the others here.

Wide is the spectrum of scientific inquiry, ranging from the philosophical— What is information?—to the banal — Where did I put that Allen wrench?

For University of Chicago graduate student Chloe Washabaugh, there is joy to be found in all of it. A Ph.D. student in quantum engineering at the Pritzker School of Molecular Engineering, Washabaugh fashions molecules into tiny quantum information processors, designing them to sense, send or store data—whatever the need.

Read more | >

Scientists have dedicated their lives to finding a cure for cancer. America became a science hub for cancer research, particularly after President Richard Nixon declared the “war on cancer” in 1971. As a result, extensive research has been published on how cancer functions and different ways to target both solid and hematologic malignancies. Unfortunately, there is currently not a cure for cancer. Although some patients are treated and enter remission, tumors can reoccur. In addition, some tumor types are harder to treat than others. Although the science community is hopeful to effectively treat each type of cancer, more work is needed to discern why some tumors are harder to treat than others.

Many tumors evade the immune system through different mechanisms and mutations. Therapy-resistant cells may stay dormant for a period of time before proliferating, which results in cancer recurrence. Additionally, different surface markers prevent immune cell activation which target cancer. This allows the tumor to proliferate without an immune cell response. Many different immunotherapies being developed target these surface markers to activate T cells, which kill or lyse infections. The type of immunotherapy that refers to the blockade of cell-to-cell interactions is known as checkpoint inhibitors. Checkpoint proteins are surface markers that help the immune cell differentiate from self. More specifically, these cells provide a signal for immune cells to avoid lysing healthy cells and protect from autoimmunity. However, tumors use a selection of checkpoint proteins to avoid immune cell detection.

Read more | >

Fungal infections have been slipping past their usual geographic boundaries and increasing in hospitals and other settings — and, as Scientific American’s Maryn McKenna has pointed out, we currently don’t have much recourse against them.

Fungal infections are incredibly hard to beat, even with modern medicine.

But MIT researchers studying the common yeast Candida albicans may have found a new effective antifungal candidate, and you’ve got some in you right now: mucus.

Read more | >